May 17th 2024
Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!
AMPLITUDE-O: Efpeglenatide Shows Promise for Reducing CV, Kidney Events in Patients with Diabetes
June 28th 2021Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.
Finerenone Provides Consistent Benefit, Irrespective of Background GLP-1 RA Use
June 26th 2021A FIDELIO-DKD analysis presented at ADA 2021 suggests the renal and cardiovascular benefits of finerenone were consistent, irrespective of background GLP-1 RA use and indicate the presence of both was associated with even greater reductions in albuminuria.
Dapagliflozin Cuts Risk of Diabetes in Patients with Chronic Kidney Disease
June 25th 2021A prespecified analysis of DAPA-CKD presented at ADA 2021 suggests use of dapagliflozin reduced the incidence of type 2 diabetes by nearly 40% among patients with chronic kidney disease but without diabetes within the phase 3 trial.
Finerenone and SGLT2 Inhibitors Could Have Additive Effect on Kidney Protection
June 25th 2021Data from an analysis of FIDELIO-DKD suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.
Study Provides Overview of ESKD, Cardiovascular Risk in Adults with Nephrotic Syndrome
June 20th 2021Comparing data from patients with primary nephrotic syndrome to matched controls in a 1:100 ratio, investigators found these patients were at a 19-fold greater risk of end-stage kidney disease and a 3-fold greater risk of acute coronary syndrome events.